Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner

Sue Haupt, Catherine Mitchell, Vincent Corneille, Jake Shortt, Stephen Fox, Pier Paolo Pandolfi, Mireia Castillo-Martin, Dennis M Bonal, Carlos Cordon-Cardo, Guillermina Lozano, Ygal Haupt

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Abstract

p53 mutations and downregulation of promyelocytic leukemia (PML) are common genetic alterations in human cancers. In healthy cells these two key tumor suppressors exist in a positive regulatory loop, promoting cell death and cellular senescence. However, the influence of their interplay on tumorigenesis has not been explored directly in vivo. The contribution of PML to mutant p53 driven cancer was evaluated in a mouse model harboring a p53 mutation (p53 (wild-type/R172H) ) that recapitulates a frequent p53 mutation (p53 (R175H) ) in human sporadic and Li-Fraumeni cancers. These mice with PML displayed perturbation of the hematopoietic compartment, manifested either as lymphoma or extramedullary hematopoiesis (EMH). EMH was associated with peripheral blood leucocytosis and macrocytic anemia, suggestive of myeloproliferative- myelodysplastic overlap. In contrast, a complete loss of PML from these mice resulted in a marked alteration in tumor profile. While the incidence of lymphomas was unaltered, EMH was not detected and the majority of mice succumbed to sarcomas. Further, males lacking PML exhibited a high incidence of soft tissue sarcomas and reduced survival, while females largely developed osteosarcomas, without impact on survival. Together, these findings demonstrate that PML is an important tumor suppressor dictating disease development in a pertinent mouse model of human cancer. Key Points: (1) A mutant p53 allele disrupts hematopoiesis in mice, by promoting lymphomas and myeloproliferative / myelodysplastic overlap. (2) Coincidental p53 allele mutation and PML loss shifts the tumor profile toward sarcoma formation, which is paralleled in human leiomyosarcomas (indicated by immunohistochemistry; IHC).
Original languageEnglish
Pages (from-to)1722 - 1731
Number of pages10
JournalCell Cycle
Volume12
Issue number11
DOIs
Publication statusPublished - 2013

Cite this

Haupt, S., Mitchell, C., Corneille, V., Shortt, J., Fox, S., Pandolfi, P. P., Castillo-Martin, M., Bonal, D. M., Cordon-Cardo, C., Lozano, G., & Haupt, Y. (2013). Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle, 12(11), 1722 - 1731. https://doi.org/10.4161/cc.24805